Please assess the completion status of the following clinical trial:

Trial Title: Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* advanced cancer patients (defined as locally recurrent or metastatic) over 18 years old with a decreased food intake for at least 2 weeks (reported by physician or subject)~* able to complete questionnaires in English~* able to provide informed consent~* life expectancy of greater than 2 months (as determined by physician)~* chemosensory complaint score \> 1~Exclusion Criteria:~* receiving enteral or parenteral feedings~* allergies or sensitivity to THC and/or sesame seed oil~* history of substance abuse or psychotic episodes~* mechanical obstruction of alimentary tract, mouth or nose~* received chemotherapy in the last 2 weeks~* received radiation therapy to the head/neck area~* brain tumor~* nausea score greater than 5 on ESAS~* history of tachyarrhythmias, angina pectoris or hypertension~* current diagnosis of liver impairment~* use of marijuana within 30 days prior to start of trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).